179 filings
Page 2 of 9
8-K
r5vkb
7 Nov 22
Ocuphire to Receive $35 Million Upfront, Nyxol Development Funding and Additional Potential Milestone Payments plus Tiered Double-Digit Royalties
4:16pm
8-K
esf2vvk2
4 Nov 22
Ocuphire Pharma Announces Financial Results for Third Quarter 2022 and Provides Corporate Update
4:39pm
8-K
z0qfsa419
14 Oct 22
Regulation FD Disclosure
11:32am
8-K
m1taaeanquyxatl 2d
12 Aug 22
Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update
7:51am
8-K
i5ddb
17 Jun 22
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
hnkjy3sbxfn8o u8qo4
10 Jun 22
Amendments to Articles of Incorporation or Bylaws
4:15pm
8-K
o40fhh3twv5
19 May 22
Regulation FD Disclosure
7:43am
8-K
cagj03l
13 May 22
Ocuphire Pharma Announces Financial Results for First Quarter 2022 and Provides Corporate Update
8:14am
8-K
yp4ijgek4 67o4xk
28 Apr 22
Other Events
7:16am
8-K
cjow5g4r 6r8ktds
29 Mar 22
Regulation FD Disclosure
8:25am
8-K
gw3njq8bm6cyi
24 Mar 22
Ocuphire Announces Financial Results for the Fourth Quarter and Year Ended 2021 and Provides Corporate Update
8:17am
8-K
5yn8mhks mqn2yt
31 Jan 22
Regulation FD Disclosure
9:53am
8-K
1ca r2f3whg88ol93qfz
31 Jan 22
Ocuphire Presenting New Data and Updates on APX3330 and Nyxol® Clinical Programs at Virtual Investor R&D Day
6:16am
8-K
0m23vuka7duj0
5 Jan 22
Completed Enrollment of Nyxol® LYNX-1 Phase 3 NVD Trial
7:05am
8-K
vuviphr40fq
15 Nov 21
Ocuphire Announces Financial Results for the Third Quarter 2021 and Provides Corporate Update
12:00am
8-K
g7nmv0xrkr85a1360mz9
12 Aug 21
Ocuphire Announces Financial Results for the Second Quarter 2021 and Provides Corporate Update
7:31am
8-K
cjf50jajt p5pyj
30 Jun 21
Regulation FD Disclosure
9:17am
8-K
ekahtxbiyx ql
23 Jun 21
Entry into a Material Definitive Agreement
4:15pm
8-K
hv2pmibkh5oa
8 Jun 21
Ocuphire Announces Closing of $15 Million Registered Direct Offering Priced At-the-Market
4:32pm
8-K/A
pn4tsw
7 Jun 21
Ocuphire Announces $15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
4:05pm